Cases & Deals

Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®

Clients Genzyme Corporation

Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.